Tenascin, an extracellular matrix protein, exerts immunomodulatory activities

C R Rüegg, R Chiquet-Ehrismann, S S Alkan, C R Rüegg, R Chiquet-Ehrismann, S S Alkan

Abstract

Tenascin is a nonubiquitous extracellular matrix protein mainly expressed during morphogenesis in embryonal life. In adults it reappears in malignant tumors and during inflammation and tissue repair. Extracellular matrix proteins can alter cell morphology, adhesion, motility, differentiation, and growth. Since cells of the immune system can express receptors for extracellular matrix, we investigated the effects of tenascin on human monocytes and T and B lymphocytes. Tenascin inhibited monocyte adhesion to fibronectin and enhanced the LFA-1 (lymphocyte function-associated antigen 1)-dependent clustering of Epstein-Barr virus-transformed B cells. The physiological consequences of the effects of tenascin were studied in several T-cell activation models. Tenascin inhibited T-cell activation induced by a soluble antigen (tetanus toxoid), alloantigens, or the mitogen concanavalin A. However, T-cell activation with phytohemagglutinin, crosslinked anti-CD3 antibody, or a mixture of ionomycin and phorbol ester was not inhibited by tenascin. Tenascin did not prevent interleukin 2-dependent T-cell growth or the cytolytic activity of an antigen-specific CD4+ T-cell clone. These results suggest that tenascin alters the adhesion properties of human monocytes, B cells, and T cells. The in vitro immunosuppressive activity of tenascin might be due to abrogation of an accessory cell function at an early stage of the interaction between antigen-presenting cells and T cells.

References

    1. Nature. 1988 Nov 3;336(6194):79-81
    1. Nature. 1988 Jun 30;333(6176):850-2
    1. Immunol Today. 1988 Apr;9(4):109-13
    1. Proc Natl Acad Sci U S A. 1985 Dec;82(23):8075-9
    1. Arteriosclerosis. 1985 Nov-Dec;5(6):581-94
    1. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2647-51
    1. Cell. 1986 Oct 10;47(1):131-9
    1. Hum Immunol. 1987 Jan;18(1):3-37
    1. Cell. 1987 Feb 27;48(4):549-54
    1. Nature. 1987 Mar 26-Apr 1;326(6111):400-3
    1. Int Arch Allergy Appl Immunol. 1987;82(3-4):302-6
    1. Proc Natl Acad Sci U S A. 1987 May;84(10):3239-43
    1. Proc Natl Acad Sci U S A. 1987 Jul;84(13):4621-5
    1. Clin Immunol Immunopathol. 1987 Aug;44(2):167-86
    1. J Cell Biol. 1987 Jul;105(1):599-608
    1. Cell. 1987 Oct 9;51(1):51-7
    1. Nature. 1987 Nov 19-25;330(6145):256-9
    1. Cell. 1987 Dec 4;51(5):813-9
    1. Science. 1987 Nov 20;238(4830):1073-9
    1. J Cell Biol. 1987 Dec;105(6 Pt 1):2569-79
    1. J Immunol. 1987 Jun 1;138(11):4004-11
    1. Annu Rev Immunol. 1987;5:561-84
    1. J Biol Chem. 1979 Jun 25;254(12):5475-82
    1. J Immunol Methods. 1979;30(1):1-10
    1. J Immunol. 1982 Jan;128(1):337-42
    1. J Exp Med. 1983 Feb 1;157(2):743-54
    1. J Cell Biol. 1983 Apr;96(4):1089-96
    1. J Theor Biol. 1982 Nov 7;99(1):31-68
    1. Cell. 1983 Dec;35(3 Pt 2):657-66
    1. J Cell Biol. 1984 Jun;98(6):1926-36
    1. J Cell Biol. 1984 Jun;98(6):1937-46
    1. Nature. 1984 Sep 20-26;311(5983):267-9
    1. Nature. 1985 Apr 11-17;314(6011):537-9
    1. Nature. 1985 Jul 11-17;316(6024):146-8
    1. J Cell Biochem. 1985;28(3):183-95
    1. Scand J Immunol. 1987 Dec;26(6):645-52
    1. Nature. 1988 Jan 7;331(6151):86-8
    1. Cell. 1988 May 6;53(3):383-90
    1. J Cell Biol. 1988 Dec;107(6 Pt 2):2757-67

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe